Quabodepistat is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Pulmonary Tuberculosis.

TBA-7371 is under development for the treatment of pulmonary tuberculosis caused by mycobacterium tuberculosis. The drug candidate is 1,4 azaindoles. It is administered through oral route in the form ...

Introduction In the realm of sports nutrition and energy supplementation, D-Ribose Powder has emerged as a popular choice for ...

D-Ribose: A key component in creating ATP, the main energy source for your cells, D-Ribose helps combat aging, restores cellular vitality, and provides sustained energy throughout your body.†* ...